Chemcrux Enterprises Limited has informed the stock exchanges that its wholly owned subsidiary, Kalichem Private Limited, has filed an application for amendment to Consent to Establish (CTE-Amendment) with the Gujarat Pollution Control Board. The application is part of the subsidiary's proposed diversification into the inorganic chemicals sector. The intimation was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was communicated to BSE Limited on 14th May 2026.

Subsidiary's Expansion into Inorganic Chemicals

Kalichem Private Limited has sought regulatory approval to add various inorganic chemicals to its existing manufacturing operations. The CTE-Amendment application has been submitted to the Gujarat Pollution Control Board, which is the relevant regulatory authority for such approvals in the state. This move represents a strategic diversification initiative by the wholly owned subsidiary into a new chemicals segment.

Facility Details

The manufacturing facility for which the CTE-Amendment has been sought is located in Vadodara, Gujarat. Key details of the facility are outlined below:

Regulatory Disclosure

The disclosure was filed by Chemcrux Enterprises Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates listed companies to inform stock exchanges of material developments. The intimation was signed by Dipika Rajpal, Company Secretary and Compliance Officer of Chemcrux Enterprises Limited, on 14th May 2026.

Chemcrux Enterprises Limited reported its audited standalone and consolidated financial results for the quarter and year ended 31st March 2026. The Board of Directors convened a meeting on 14th May 2026 to approve the results, recommend a final dividend, and approve the incorporation of a non-profit wholly-owned subsidiary under Section 8 of the Companies Act, 2013. The board meeting commenced at 11:30 A.M. and concluded at 04:10 P.M.

Financial Performance

For the financial year ended 31st March 2026, the company reported a standalone net profit of INR 544.97 lacs, an increase of 30.1% compared to INR 418.86 lacs in the previous year. Revenue from operations for the year stood at INR 8,257.92 lacs, up from INR 7,025.39 lacs in the prior year. For the quarter ended 31st March 2026, net profit was INR 198.68 lacs.

On a consolidated basis, net profit for the year was INR 373.08 lacs, compared to INR 391.30 lacs in the previous year. Total consolidated revenue for FY26 was INR 8,267.13 lacs. The company's subsidiary, Kalichem Private Limited, became a wholly-owned subsidiary during the year following the acquisition of the remaining 50% stake in February 2025.

The following table summarizes the standalone financial performance for the year:

The statutory auditors, M/s Naresh & Co., Chartered Accountants, issued an unmodified opinion on the audited standalone and consolidated financial statements.

Dividend Declaration

The Board of Directors recommended a final dividend of 10% (Re. 1/- per share) on equity shares of Rs. 10/- each for the financial year 2025-26. This dividend is subject to the approval of shareholders at the ensuing Annual General Meeting.

Section 8 Subsidiary Incorporation

The Board also approved the incorporation of a non-profit making company under Section 8 of the Companies Act, 2013 as a wholly-owned subsidiary of Chemcrux Enterprises. The proposed subsidiary is intended to fulfill the company's CSR obligations and will operate with objects including promotion of commerce, art, science, sports, education, research, social welfare, healthcare, charity, and protection of environment, among other activities enumerated in Schedule VII of the Companies Act, 2013.

The key details of the proposed subsidiary are summarized below:

The name of the proposed wholly-owned subsidiary will be as approved by the Ministry of Corporate Affairs, Government of India, and a further update will be provided once the subsidiary is incorporated. The incorporation is subject to MCA and other applicable regulatory approvals, and no indicative timeline has been specified pending those approvals. Upon incorporation, the proposed wholly-owned subsidiary will be treated as a related party of the company.